LOGIC MODEL FOR A DISEASE FOCUSED GRANT-MAKING PROGRAM Sindy Escobar-Alvarez, Program Officer Doris Duke Charitable Foundation

RESOURCES INPUTS	ACTIVITIES	OUTPUTS	OUTCOMES	IMPACT
HUMAN	PROCESSES	GRANT-MAKING	SHORT TERM (1-3 YR)	PATIENT
 Program staff Program staff Support staff Contractors Scientific Advisory Council Other scientific advisors Past grantees Patients with the disease Patient advocacy groups FINANCIAL Grant making budget Operations budget Operations budget ORGANIZATIONAL Infrastructure for program implementation Support for implementation of the program NETWORKS HRA membership Other funders of the disease area to be supported TIME Timeframe to implementation FACILITIES Meeting space SUPPLIES AND EQUIPMENT IT resources 	 Determine needs for funding in the disease area of interest Define scope of areas for funding Define target investigators for the funding opportunity Determine the appropriate award size and length Identify the appropriate funding mechanism (competition vs. curated grants) Determine the appropriate review process (traditional scientific peer-review, mix of industry and academic scientists, non-traditional reviewers panel such as VC, etc) TOOLS Literature searches Interviews Informal discussions EVENTS Panel discussions TECHNOLOGY Application portal ACTIONS Distribution of RFP (electronic, press release, etc) Enable portal for receipt of applications Recruit reviewers COMPETITION # of applications 	 Number of awards Amount (\$) of awards Types of projects recommended for funding (consider scope of funding and grant portfolio) ENRICHMENT ACTIVITIES FOR GRANTEES Grantee meetings Meetings between grantees and patient advocacy groups (consider other advisors or relevant parties) Other activities? Meetings between grantees and facilitators of commercialization (this includes advisors and potential investors) Support for exploration of commercialization 	 Shoki TERM (1-5 TK) Scientific knowledge Scientific resources Inventions Publications Collaborations Dissemination through presentations (scientific and non-scientific) Validated knowledge with the potential to translate into therapies LONG TERM (7-10 YR) Application of validated knowledge for clinical application (large clinical application (large clinical trials) Translation of knowledge into other disease areas Patent portfolio to protect the inventions Involvement of other parties in the project (for commercialization and expansion of the project scope) 	 New safe and effective therapy for the disease Improved health of target population SCIENTIFIC COMMUNITY Understanding of the mechanism of disease Application of knowledge to other disease areas Development of new treatments based on other mechanisms of disease